Cargando…
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major the...
Autores principales: | Khoo, Joan, Rayner, Christopher K, Jones, Karen L, Horowitz, Michael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731024/ https://www.ncbi.nlm.nih.gov/pubmed/19707284 |
Ejemplares similares
-
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
por: Marathe, Chinmay S., et al.
Publicado: (2011) -
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
por: Marathe, Chinmay S., et al.
Publicado: (2013) -
New prospects for incretin‐related drugs in the treatment of type 2 diabetes
por: Kimura, Tomohiko, et al.
Publicado: (2020) -
Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes
por: Gleeson, Jeremy M., et al.
Publicado: (2005) -
Effects of Intraduodenal Glutamine on Incretin Hormone and Insulin Release, the Glycemic Response to an Intraduodenal Glucose Infusion, and Antropyloroduodenal Motility in Health and Type 2 Diabetes
por: Chang, Jessica, et al.
Publicado: (2013)